Alborz Yazdi
Oprichter bij Exavir Therapeutics
Profiel
Alborz Yazdi is the founder of Exavir Therapeutics.
Prior to that, he worked as an Analyst at Passaic Capital Management LLC from 2020 to 2022 and as an Associate at Bain Capital Life Sciences LP from 2019 to 2020.
He completed his undergraduate degree at Yale University.
Actieve functies van Alborz Yazdi
Bedrijven | Functie | Begin |
---|---|---|
Exavir Therapeutics
Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Oprichter | - |
Eerdere bekende functies van Alborz Yazdi
Bedrijven | Functie | Einde |
---|---|---|
Passaic Capital Management LLC
Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Analyst-Equity | 01-02-2022 |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Private Equity Analist | 01-10-2020 |
Opleiding van Alborz Yazdi
Yale University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Passaic Capital Management LLC
Passaic Capital Management LLC Investment ManagersFinance Passaic Capital Management LLC (Passaic Capital) is an alternative investment firm headquartered in Albany, New York. The firm was founded in 2013 as a hedge fund platform of Millennium Management LLC. Passaic Capital manages a long/short equity portfolio for high net worth investors. | Finance |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts. | Finance |
Exavir Therapeutics
Exavir Therapeutics Miscellaneous Commercial ServicesCommercial Services Exavir Therapeutics is an American preclinical stage biotechnology company founded by Alborz Yazdi, Howard E. Gendelman, Benson Edagwa, dedicated to developing ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders. The company's pipeline includes several long-acting antiviral nanomedicines as well as an earlier stage HIV cure program that utilizes CRISPR nucleases and proprietary LNP formulations to precisely deliver pro-viral DNA excision payloads to tissues that are the target of HIV. The company aims to eliminate HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics. HIV is one of the world's most serious public health challenges, and Exavir Therapeutics is developing ultra-long-acting nanomedicines for HIV, other viral infections, and CNS disorders. | Commercial Services |